Alsigma to invest 1.8 billion rubles in launching production of antitumor drugs in Dubna

According to the Minister of Investment, Industry and Science of the Moscow Region Ekaterina Zinovieva, the enterprise will be located on a territory of about 5.2 thousand square meters and will create 55 jobs. After reaching full capacity, the plant will produce 140 million tablets and capsules per year. "Implementation of the project will help avoid interruptions in the supply of similar imported medicines," Zinovieva noted.

The project will be implemented in two stages. The first is planned for 2027, completion is expected in 2029. In August 2024, investments in the Alsigma LLC project were estimated at 780 million rubles.

According to SPARK-Interfax, Alsigma LLC was registered in Dubna on June 25, 2024. The company's main activity is the production of medicines and materials for medical and veterinary use. The company is wholly owned by Altegra JSC (a subsidiary of AlPharma). In 2024, the legal entity's loss amounted to 4 million rubles with no revenue.

In 2021, Altegra announced its intention to invest 365 million rubles in the development of production technologies in the Dubna SEZ. The company planned to develop not only technologies for the production of generics, but also innovative drugs patented in the form of sterile powders for the preparation of solutions.